Anhui Anke Biotechnology (Group) Co., Ltd.

Anhui Anke Biotechnology (Group) Co., Ltd., also known as AnkeBio, is a state-level high-tech enterprise in China focused on the bio-pharmaceutical industry. Established as one of the earliest companies in the country dedicated to the research, development, production, and sales of genetic engineering drugs, AnkeBio has built a comprehensive industrial chain encompassing various biotechnological products, modern Chinese patent medicine, synthetic drugs, and peptide drugs. The company's main product lines include biologics such as Human Growth Hormone (Ansomone®) and Recombinant Human Interferon alpha 2b (Anterferon®), as well as antibody drugs like trastuzumab (Antrastuin®). AnkeBio also produces modern Chinese patent medicines, polypeptide drugs, and synthetic drugs. With a robust research and development system, the company continuously innovates and expands its product offerings, targeting areas such as anti-tumor treatments and cutting-edge technologies like cell therapy and mRNA drugs. AnkeBio's marketing strategy is supported by specialized divisions and a professional team, enhancing its competitive position in the pharmaceutical market.

Anhui Anke Biotechnology (Group) Co, Ltd. is one of the earliest enterprises in China in the research and development, production and sales of genetic engineering drugs. Based on the field of biomedicine, the company takes genetic engineering drugs as the lead, combined with other biomedicines, small molecule drugs, polypeptide drugs, traditional Chinese medicine patches, forensic DNA testing, etc., and has established a whole industrial chain system of research and development, production and sales. As the company continues to grow, its competitive advantages in new product development, production management, quality control, and market promotion are constantly strengthening. 1.Advantages of Product technology and industrialization Anhui Anke Biotechnology (Group) Co, Ltd. has always focused on the upgrading of main products and new product research and development, and has a sound research and development system. Since its establishment, in addition to constantly improving the quality of main products and enriching product categories, after years of platform construction and technology accumulation, it has acquired successful experience in independent research and development and industrialization of many new drugs. The company actively seizes the trends of cuuting-edge technologies and innovations in the industry, taking market demand as the starting point, and continuously innovates products through independent R&D and cooperation with extrnal to enrich the product line and enhance product competitiveness. The company's biological products, Human Growth Hormone (Ansomone®) and Human Interferon alpha 2b (Anterferon®), lead in research and development levels, brand advantages, and market share within their respective specialized fields. Its first antibody drug, trastuzumab (Antrastuin®), ranks among the top tier of trastuzumab antibody drugs domestically. On this basis, the company is promoting the layout of the innovative drug product pipeline and planning for cutting-edge technologies actively, targeting multiple new drug studies such as monoclonal antibodies, bispecific antibodies, and innovative ADC drugs based on market demand and technological prospects, further enriching its tumor treatment product pipeline. Moreover, the company keeps pace with the latest trends in biological new drug R&D internationally and has made strategic layouts in cutting-edge technologies such as cell therapy, oncolytic viruses, and mRNA drugs through projection cooperations and equity investment, reserving gene therapy products, and will continue to make foward-looking layouts in biomedical frontier innovation technologies. 2.Marketing team and sales advantages (1) Adhering to the Core Values of Upholding Orthodoxy and Innovating The company's existing products cover reproductive growth and development, antiviral, and cancer treatment areas. To optimize decision-making efficiency and promote efficient marketing operations, the parent company has established three core divisions: Pediatric Drug Division, Reproductive Antiviral Drug Division, and Anti-Cancer Drug Division, achieving flat management and deepening its focus on specialized field; subsidiaries also adjust and innovate their marketing models based on their product characteristics, industry policy environment, market changes, and company strategic planning, optimizing organizational structures. The company has built a professional marketing team with a background in biology, medicine, pharmacy, and nursing, and has established several dedicated academic promotion teams to enhance the multi-dimensional value of products. On the basis of consolidating the existing market, the company has promoted business strategy of core products and new products in a comprehensive and in-depth manner, to steadily expand product coverage. It conducts refined promotions tailored to pediatric products, antiviral drugs, targeted cancer drugs, biologic detection products, traditional Chinese medicine products, health nutrition products, etc., strengthening brand value dissemination and online and offline promotions, and constructing a digital value marketing closed-loop system. (2)Synergistic Development With professional promotion, rich market management experience, meticulous after-sales service, and product resource integration advantages, the company has established a good user base with medical institutions. The company's products cover the marketing network of more than 4,000 large and medium-sized hospitals across the country. The company's products have been highly recognized by doctors and patients. By combining online and offline services, the company provides patients with a full chain of services, including disease health education and management, safe drug knowledge popularization, etc., to improve market coverage and penetration rate, creating favorable conditions for the growth of domestic market sales. (3)Brand Value Brand building is one of the core competitiveness of the company, after 30 years of cultivation and operation, the core brands of the company, such as "Ansomone", "Anterferon", and "Yuliangqing Traditional Chinese Brand", have all become well-known brands in the industry and are among the leading brands in their respective sub-sectors. With the launch of the company's new anti-cancer drug product "Antrastuin" in a new sub-sector, the company's products have officially entered the oncology market, further enhancing the brand's influence. Meanwhile, the company's health-functional nutritional product 'ANKE KIDS' has successfully expanded into new specified market. The company has newly established multimedia center, combining online and offline efforts, leveraging video platforms, social media, and other emerging channels to continuously conduct brand promotion activities, promoting deeper and wider coverage of the company's products. 3.Industrial synergy advantage SOHO-YIMING Pharmaceuticals Co., Ltd., wholly-owned by AnkeBio, is comprehensive in researching and producing polypeptide APIs, having more than 20 invention patents and a bunch of products under clinical trials. The polypeptide products have high, stable quality and rich variety. The breadth and yield of peptide APIs are on the leading position in China and have obvious competitive advantages. As an innovative high-tech enterprise in the field of forensic DNA testing in China, a wholly-owned subsidiary by AnkeBio, AGCU ScienTech Incorporation has established a multiplex PCR&CE amplification detection platform with outstanding advantages, independently developed a full range of global forensic DNA detection kits, broken the monopoly of foreign technology. In recent years, its product technology has played an active role in assisting in the detection of major difficult cases and assisting in solving public safety emergencies, and established a good market image and social image. Yu Liangqing, a holding subsidiary, is one of the first batch of "century-old brand" enterprises recognized by the Ministry of Commerce, and its main products are topical plasters of proprietary Chinese medicines represented by blood and pain relief ointment, which has a high reputation and has obtained a high market share and competitive advantage. While maintaining the market of traditional proprietary Chinese medicine products, we also carry out product innovation and actively develop new plaster products such as transdermal absorption to meet the needs of patients. Bo shengji is a national high-tech enterprise with breakthrough tumor cell immunotherapy technology and cell drug product research and development as the main development goal, focusing on developing breakthrough drugs of international leading level ,such as First-in-class and Best-in-class CAR-T cell drugs, and a number of cell products have entered the clinical verification stage, and its product indications involve hematological tumors and solid tumors.